- Home
- SENEA vs CSTL Comparison
SENEA vs CSTL Comparison
Compare SENEA & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SENEA
- CSTL
- Stock Information
- Founded
- SENEA 1949
- CSTL 2007
- Country
- SENEA United States
- CSTL United States
- Employees
- SENEA N/A
- CSTL N/A
- Industry
- SENEA Packaged Foods
- CSTL Medical Specialities
- Sector
- SENEA Consumer Staples
- CSTL Health Care
- Exchange
- SENEA Nasdaq
- CSTL Nasdaq
- Market Cap
- SENEA 772.5M
- CSTL 697.9M
- IPO Year
- SENEA N/A
- CSTL 2019
- Fundamental
- Price
- SENEA $109.45
- CSTL $21.42
- Analyst Decision
- SENEA
- CSTL Strong Buy
- Analyst Count
- SENEA 0
- CSTL 6
- Target Price
- SENEA N/A
- CSTL $37.67
- AVG Volume (30 Days)
- SENEA 52.3K
- CSTL 449.4K
- Earning Date
- SENEA 11-05-2025
- CSTL 11-03-2025
- Dividend Yield
- SENEA N/A
- CSTL N/A
- EPS Growth
- SENEA N/A
- CSTL N/A
- EPS
- SENEA 6.24
- CSTL N/A
- Revenue
- SENEA $1,571,618,000.00
- CSTL $346,269,000.00
- Revenue This Year
- SENEA N/A
- CSTL N/A
- Revenue Next Year
- SENEA N/A
- CSTL N/A
- P/E Ratio
- SENEA $17.55
- CSTL N/A
- Revenue Growth
- SENEA 7.30
- CSTL 20.40
- 52 Week Low
- SENEA $59.96
- CSTL $14.59
- 52 Week High
- SENEA $115.40
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- SENEA 52.54
- CSTL 49.02
- Support Level
- SENEA $108.34
- CSTL $22.54
- Resistance Level
- SENEA $111.68
- CSTL $24.74
- Average True Range (ATR)
- SENEA 2.50
- CSTL 1.13
- MACD
- SENEA -0.44
- CSTL -0.19
- Stochastic Oscillator
- SENEA 24.20
- CSTL 24.37
About SENEA Seneca Foods Corp.
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.